Covariates | Overall | APLs | t(8;21)- AMLs | inv(16)-AMLs | NK-AMLs |
---|---|---|---|---|---|
Samples* | N = 206 | N = 40 | N = 39 | N = 52 | N = 57 |
Groups | |||||
Training Set AML samples | 71 | 14 | 14 | 15 | 28 |
Training Set NBM&samples | 18 | -- | -- | -- | -- |
Test Set AML samples* | 111 | 24 | 23 | 35 | 29 |
Test Set AML cell lines | 6 | 2 | 2 | 2 | -- |
Samples with optimal QCC# | |||||
Blast % < 60% (undiluted) | 22 | 3 | 5 | 11 | 3 |
Diluted at 50% | 28 | 5 | 5 | 5 | 13 |
Diluted at 75% | 27 | 5 | 4 | 5 | 13 |
Diluted at 90% | 12 | 4 | 4 | 4 | 0 |
Diluted at 95% | 12 | 4 | 4 | 4 | 0 |
Overall, blasts < 60% | 101 | 21 | 22 | 29 | 29 |
Overall, blasts ≥ 40% < 60% | 23 | 2 | 2 | 6 | 13 |
Overall, blasts ≥ 20% < 40% | 40 | 6 | 9 | 10 | 15 |
Overall, blasts ≥ 10% < 20% | 15 | 4 | 4 | 6 | 1 |
Overall, blasts ≥ 5% < 10% | 14 | 5 | 4 | 5 | 0 |
Overall, blasts < 5% | 9 | 4 | 3 | 2 | 0 |
Samples with poor QCC# | 10 | 3 | 1 | 6 | 0 |
cRNA $ < 750 ng | 7 | 1 | 1 | 5 | 0 |
Low RIN% | 2 | 2 | 0 | 0 | 0 |
Low RIN + low cRNA | 1 | 0 | 0 | 1 | 0 |